Clinical Trials

Inclusion Criteria:

• Normal postmenopausal women
• Aged 70 or greater

Exclusion Criteria:

• History of diabetes or hemoglobin A1c ≥ 6.5%.
• Abnormal screening labs.
• Presence of significant liver or kidney disease. heart failure.
• Malignancy (including myeloma).
• Malabsorption, including gastric bypass / reduction, Crohn’s disease.
• Hyperthyroidism.
• Acromegaly.
• Cushing’s syndrome.
• Hypopituitarism.
• Subjects with a fracture within the past six months.
• Undergoing treatment with any medications that affect bone turnover, including the following:
  • adrenocorticosteroids (> 3 months at any time or > 10 days within the previous yr), anticonvulsant therapy (within the previous year);
  • pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal);
  • calcium supplementation of > 1200 mg/d (within the preceding 3 months);
  • bisphosphonates (within the past 3 yrs);
  • denosumab;
  • estrogen (E) therapy or treatment with a selective E receptor modulator, or teriparatide (within the past year);
  • β-blockers.
• Subjects on therapeutic doses of anti-coagulants (e.g. warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.).
• Subjects taking anti-arrhythmic medications known to cause QTc prolongation.
• Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax.
• Subjects currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy.
• Subjects taking H2 antagonists
• Tyrosine kinase inhibitor therapy.
• Subjects not having a PBTL p16INK4a  mRNA expression level >95 percentile of young female controls.
• Known hypersensitivity or allergy to Dasatinib, Quercetin, or Fisetin.
• Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus or sirolimus). If antifungals are absolutely necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic.
• Subjects on antiplatelet agents. Subjects may continue their previous regimen between study drug dosing periods.
• Subjects on quinolone antibiotic therapy for treatment or for prevention of infections within ten days.
• Subjects taking proton pump inhibitors and to discontinue therapy for one week before and two weeks following enrollment.
• Additional exclusion criteria apply